ESC Recap Part 2: ECLS-SHOCK, FIRE, MULTISTARS-AMI, HEART FID, and DANPACE II are the trials John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I. Cardiogenic Shock

ECMO for Shock in Acute MI Won't Help, May Harm: ECLS-SHOCK https://www.medscape.com/viewarticle/995882

- ECLS-SHOCK trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307227

- ECMO-CS trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949

II. FIRE TRIAL

FIRE a Win for Physiology-Guided MI Complete Revascularization in Older Patients https://www.medscape.com/viewarticle/995875

- FIRE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300468

- COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775

III. Immediate vs Staged Revascularization

Parity for Prompt vs Staged STEMI Complete Revascularization: MULTISTARS-AMI https://www.medscape.com/viewarticle/995961

- MULTISTARS AMI trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307823

- Complete Revascularization Now Compulsory? MULTISTARS-AMI and FIRE in Context https://www.medscape.com/viewarticle/995676

IV. Iron-Supplementation in Heart Failure

IV Iron Shows Only Modest Benefit in HF: HEART-FID https://www.medscape.com/viewarticle/995874

- HEART-FID https://www.nejm.org/doi/full/10.1056/NEJMoa2304968

- EHJ meta-analysis of Iron Supplementation https://doi.org/10.1093/eurheartj/ehad586

V. AF Prevention with Pacing

Minimizing Atrial Pacing No Benefit in Sinus Node Disease: DANPACE II https://www.medscape.com/viewarticle/996076

- DANPACE II https://doi.org/10.1093/eurheartj/ehad564

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine. https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]